Constituent Dose Ranges in the GLOW Peptide Research Literature

The short version

There is no validated dose for the GLOW peptide blend. The blend has never been dosed in a controlled human trial — no study has measured what amount of GHK-Cu, BPC-157 and TB-500 together is safe or effective in humans. What the research literature does contain is dose information for each peptide individually, studied separately in animals or, in a handful of small pilots, in humans. Those figures are set out here as research context — what was administered to which species at which dose by which route in which study. They are not a personal recommendation, and they cannot be applied to the blend.

GLOW peptide dosage: no validated blend dose exists

A commonly cited research-label convention for the GLOW blend runs 10 mg BPC-157 / 10 mg TB-500 / 50 mg GHK-Cu per vial. That ratio appears on supplier labels and in community protocols; it is a formulation convention, not a clinically validated dose. No trial has established whether it is effective, safe, or optimal for any outcome in humans.

Glow peptide injection: routes studied for each constituent. The routes used in published research are constituent-specific and do not validate a co-formulated subcutaneous GLOW injection:

• GHK-Cu: predominantly topical (creams, serums, microneedle and liposomal delivery systems) in dermatology and cosmetic research, plus some intraperitoneal and intranasal routes in animal models.
• BPC-157: intraperitoneal and intramuscular in animals; intravenous in a 2-subject human safety pilot.
• TB-500 / Tb4: topical and intraperitoneal in animal wound models; intravenous in a human Phase 1 safety study of full-length thymosin beta-4.

Community protocols describe subcutaneous injection of a reconstituted GLOW blend. No peer-reviewed pharmacology supports subcutaneous blend dosing; that route is extrapolated from the individual-constituent animal literature and from practice patterns, not from a controlled study.

GHK-Cu dose and stability context

In vitro, GHK-Cu stimulates fibroblast collagen synthesis at concentrations from 10⁻¹² to 10⁻⁹ M — picomolar to nanomolar, which is remarkably low ^[1]. Commercial topical cosmetic formulations run approximately 0.05% to 2% (w/w). In animal intraperitoneal models the doses studied are higher; human topical-cosmetic doses are not directly comparable to systemic doses and should not be translated.

Glow injection: the GHK-Cu stability note. The GHK-Cu complex is most stable near pH 5–6.5; the characteristic blue-violet color of a correctly reconstituted solution confirms an intact Cu(II) complex. Strong reducing agents and low-pH actives — notably ascorbic acid (vitamin C) — can disrupt the copper coordination. Co-formulating a copper complex with two other peptides that may have different optimal pH ranges raises compatibility questions for GLOW stability that have not been studied for the blend specifically. Lyophilized powders reconstituted with bacteriostatic water (sterile water containing 0.9% benzyl alcohol, which inhibits bacterial growth over multiple uses) should be refrigerated.

BPC-157 dose context and pharmacokinetics

In the foundational rat Achilles transection study, once-daily intraperitoneal BPC-157 at 10 μg/kg, 10 ng/kg, or 10 pg/kg body weight was effective, with dose-response characteristics across a wide range ^[3]. A 2-subject human IV safety pilot used 10 mg then 20 mg — a figure cited in the pharmacokinetic literature, not a validated therapeutic dose. A 2025 narrative review noted that no large-scale human dose-finding study has been conducted and that the pharmacokinetic profile in humans is poorly characterized ^[7].

BPC-157 has a short elimination half-life — under 30 minutes in rats and dogs — with linear kinetics and rapid breakdown to amino acids. That short half-life means the circulating compound clears quickly after a single administration; whether daily injections produce meaningful tissue-level accumulation is unstudied in humans.

TB-500 and thymosin beta-4 dose context

The wound-healing study that produced the 42% re-epithelialization increase at day 4 used topical and intraperitoneal full-length thymosin beta-4; the same study found that as little as 10 pg stimulated keratinocyte migration 2–3-fold ^[5]. A human Phase 1 safety study of full-length Tb4 administered intravenously to 40 volunteers at doses of 42, 140, 420 and 1260 mg found dose-proportional pharmacokinetics with half-life increasing with dose; no serious adverse events were reported at any dose ^[8]. That human safety study used the full 43-amino-acid protein, not the commercial TB-500 7-mer fragment. The pharmacokinetics of the Ac-LKKTETQ fragment in humans have not been characterized.

GLOW blend combined pharmacokinetics: unstudied. The three constituents clear at very different rates — the small GHK tripeptide (MW approximately 402.9 Da) and the short-lived BPC-157 (half-life under 30 minutes in animals) versus the Tb4 fragment. Whether co-formulation alters any constituent's kinetics, or whether interactions occur at the peptide level, is entirely unstudied for the GLOW combination.

GLOW peptide injection: reconstitution context

For the individual lyophilized peptides — BPC-157 and TB-500 in particular — standard research handling involves reconstituting the freeze-dried powder in bacteriostatic water. The appropriate volume determines the concentration per unit. Community protocols for the GLOW blend describe reconstituting a vial containing all three peptides together, but no published stability data confirm that GHK-Cu, BPC-157 and TB-500 remain compatible and potent together in a single solution over the periods implied by community use. Theoretical compatibility concerns (copper redox chemistry, pH) remain unresolved for the GLOW combination specifically.